Table 1.
Baseline clinical characteristics at time of study enrollment.
| Patients, n | 29 |
| Median age (range), years | 71 (44–83) |
| Median PSA (range), ng/mL | 78 (2–908) |
| Extent of disease | |
| Bone only | 10 (33%) |
| Bone and LAD | 15 (50%) |
| Bone and LAD/visceral disease | 3 (10%) |
| LAD only | 2 (7%) |
| Median tumor fraction in prestudy biopsy | 55% (4–88%) |
| Previous therapies, n | |
| Radical prostatectomy | 5 |
| Definitive radiotherapy | 6 |
| Neither (metastatic at diagnosis) | 19 |
| Systemic therapy | |
| Combined androgen blockade | 8 |
| Bicalutamide | 9 |
| Nilutamide/flutamide | 3 |
| High-dose ketoconazole | 5 |
| Diethylstilbestrol | 2 |
| Sipuleucel-T | 4 |
| Docetaxel | 4 (1 CSPC) |
| Lines of therapy for CRPC | |
| 0 | 7 |
| 1 | 14 |
| 2 | 3 |
| 3–4 | 5 |
Abbreviations: CSPC, castration-sensitive prostate cancer; LAD, lymphadenopathy.